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The neuropeptide neurotensin (NT) elicits numerous pharmacological effects
through three different receptors (NTSR1, NTSR2, and NTSR3 also called sortilin).
Pharmacological approaches and generation of NTSR1 and NTSR2-deficient mice
allowed to determine the NT-induced antipsychotic like behavior, the inhibitory of weak
fear memory and the nociceptive signaling in a rat formalin tonic pain model to NTSR1.
Conversely, the effects of NT on thermal and tonic nociceptions were mediated by
NTSR2. However, the role of NTSR3/sortilin on the neurotensinergic system was not
investigated. Here, by using C57Bl/6J mouse model in which the gene coding for
NTSR3/sortilin has been inactivated, we observed a modification of the expression of
both NTSR2 and NT itself. Quantitative PCR and protein expression using Western blot
analyses and AlphaLisaTM technology resulted in the observation that brain NTSR2 as
well as brain and blood NT were 2-fold increased in KO mice leading to a resistance
of these mice to thermal and chemical pain. These data confirm that NTSR3/sortilin
interacts with other NT receptors (i.e., NTSR2) and that its deletion modifies also the
affinity of this receptor to NT.
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INTRODUCTION
The endogenous neuropeptide NT is involved in numerous biological functions both in the brain
and in periphery organs (for review see Kleczkowska and Lipkowski, 2013). These processes include
dopamine transmission (Kitabgi et al., 1989), analgesia (Dobner, 2006), hypothermia (Popp et al.,
2007) and hormonal activity regulation (Rostene and Alexander, 1997; Beraud-Dufour et al., 2010).
The effects of NT are the consequence of its interaction with three different NT receptors (NTSRs).
NTSR1 and NTSR2 are both seven transmembrane (TM) domain G protein-coupled receptors
(GPCR) whereas NTSR3 is a single TM domain type I receptor that displays 100% homology with
the sorting protein, sortilin (Petersen et al., 1997; Mazella et al., 1998; Mazella, 2001).
The use of selective agonists and antagonists as well as the generation of NTSR1 and
NTSR2-deficient mice permitted the determination of the role of these two GPCRs in the
NT-induced central effects. The high affinity NTSR1, insensitive to levocabastine, is involved
in a series of actions of NT including the antipsychotic like behavior (Mechanic et al., 2009),
the inhibition of weak fear memory (Yamada et al., 2010) and the nociceptive signaling in a
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rat formalin tonic pain model (Roussy et al., 2008). The deletion
in mice of the low affinity NTSR2, sensitive to levocabastine,
results in the loss of thermal (Maeno et al., 2004) and tonic
nociception of NT (Roussy et al., 2009). Levocabastine is a well
characterized compound able to selectively bind by competition
with NT to the low affinity NT receptor (i.e., NTSR2) without
affecting the binding of NT to NTSR1 in murine brain (Kitabgi
et al., 1987; Mazella et al., 1998).
At the level of the neurotensinergic system, NTSR3/sortilin
has been shown to interact with NTSR1 tomodulate NT signaling
in HT29 cells (Martin et al., 2002) and with NTSR2 to contribute
to the protective effect of NT in pancreatic beta cells (Beraud-
Dufour et al., 2009). NTSR3/sortilin is a protein that belongs to
the Vps10p protein family (Marcusson et al., 1994) and displays
multiple functions and may act as a receptor or a co-receptor
as well as a sorting partner to trigger proteins either to the
degradation pathway or to the plasma membrane (reviewed
in Mazella, 2001; Hermey, 2009; Carlo et al., 2014; Wilson
et al., 2014). Two different NTSR3/sortilin deficient mice have
been generated (Nykjaer et al., 2004; Zeng et al., 2009). These
mice have been mainly used to study the sorting functions of
NTSR3/sortilin including rapid endocytosis of progranulin to
lysosomes (Hu et al., 2010; Tall and Ai, 2011).
However, nothing is known about the consequence of
NTSR3/sortilin deletion on the neurotensinergic system in mice.
Therefore, we investigated the fate of NTSR1, NTSR2 and NT
expression in the NTSR3/sortilin-deficient mice developed by the
Morales’s group (Zeng et al., 2009; Musunuru et al., 2010). In
the present study, we observed that the lack of NTSR3/sortilin
led to the increase of NTSR2 and NT expression in the adult
mouse brain. The higher levels of both NTSR2 and NT in the
brain of NTSR3/sortilin-deficient mice resulted, as expected, in
the loss of sensitivity of painmeasured with thermal and chemical
nociceptive tests.
MATERIALS AND METHODS
Materials
Neurotensin (NT) was purchased from Peninsula Laboratories.
125I-Tyr3-NT was prepared and purified as described (Sadoul
et al., 1984). The brain permeant JT212 (formerly called
ABS212) was kindly provided by Dr. Thomas Dix (Charleston,
USA). Levocabastine was generously provided by A. Schotte
(Belgium). Bovine Serum Albumin (BSA), mammalian protease
and phosphatase inhibitor cocktails were from Sigma France.
Rabbit polyclonal antibodies against NTSR1 and NTSR2 were
from SantaCruz technologies (USA). The monoclonal antibody
against NTSR3 was from BD Bioscience. HRP conjugated goat
anti-rabbit and anti-mouse were from Cell Signaling. Sortilin
(sort1; Uniprot number: Q6PHU5) knockout mice were kindly
provided by Dr. Carlos Morales (Montreal, Canada).
Binding Experiments
Binding experiments were carried out on brain homogenates
prepared as previously described (Zsurger et al., 1994). 125I-NT
(2000 Ci/mmol) has been prepared and purified as described
(Sadoul et al., 1984). Homogenates (60 µg of protein) were
incubated in 250 µl of 50 mM Tris-HCl, pH 7.5, containing
0.2% BSA and 1 mM MgCl2 at 25◦C for 30 min with increasing
concentrations of 125I-NT alone (from 50 to 400 pM) or
isotopically diluted by unlabeled NT (from 0.1 to 25 nM) in
the absence or in the presence of levocabastine (1 µM). Binding
experiments were terminated by addition of 2 ml ice-cold buffer.
Radioactivity bound to homogenate was separated from free
ligand by filtration under reduced pressure through cellulose
acetate Sartorius filters (SM11107, 0.2 µm pore size). Filters
and tubes were rapidly washed twice with 2 ml of incubation
buffer. Radioactivity retained on filters was counted with a
Packard g-counter. Binding parameters (dissociation constant
Kd and maximal binding capacities Bmax) were determined by
computerized Scatchard analysis.
Primer Design and Real-Time qPCR
Mice were killed by cervical dislocation. The brain was dissected
and immediately frozen in liquid nitrogen. Total RNA was
extracted following the Tri Reagent method (Sigma). 2 µg
of total RNA was digested with Turbo Dnase (Ambion) and
used as template in the reverse transcription reaction with
the SuperScript III Reverse Transcriptase and Random Primers
(Invitrogen). Primers (Eurogentec) were specific for sequences
of NT, NTSR1 (Uniprot number: O88319), NTSR2 (Uniprot
number: P70310), GAPDH and CycloD (Table 1).
Real-time qPCR was performed on the LightCyclerTM 480
(Roche) using the LightCyclerTM 480 SYBR Green 1 Master
mix (Roche). PCR reactions were performed in 20 µl volume
containing 16 ng cDNA, 10 µl 2x LightCyclerTM 480 SYBR Green
1 Master mix and 1 µl of primer mix (10 µM forward primer,
10 µM reverse primer). The PCR profile was as follows: 5 min at
95◦C, followed by 45 cycles of 10 s at 95◦C, 10 s at 60◦C and 10 s
at 72◦C.
The Ct value of each gene of interest was normalized to
the Ct of the reference genes as follows: DC = Ctgoi-Ctref
with Ctref = (CtGAPDH x CtCycloD)
(1/2) with goi = gene of
interest, and ref = reference gene. DDCT = DCT experimental
condition - DCT control condition. Values were expressed as
2−DDCt normalized using C57Bl/6J as a control.
Animals
Adult male mice, weighing 20–25 g (8–10 weeks old) were used in
this study. The animals were housed under controlled laboratory
TABLE 1 | Oligonucleotides used for qPCR.
mGAPDH-qPCR-F : AAGAGGGATGCTGCCCTTA
mGAPDH-qPCR-R : TTTTGTCTACGGGACGAGGA
mCycloD-qPCR-F : AAGGATGGCAAGGATTGAAA
mCycloD-qPCR-R : GCAATTCTGCCTGGATAGCTT
mNTs-qPCR-F : TGACTCTCCTGGCTTTCAGC
mNTs-qPCR-R : TCCAGGGCTCTCACATCTTC
mNTR1-qPCR-F2 : GGCAATTCCTCAGAATCCATCC
mNTR1-qPCR-R2 : ATACAGCGGTCACCAGCAC
mNTR2-qPCR-F : TGCACGGTGCTAGTAAGTCG
mNTR2-qPCR-R : AAGGAGACCAGCACGTTCAC
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conditions (in accordance with the FELASA guidelines and
recommendations), 6 mice/cage with a 12 h dark-light cycle,
a temperature of 21 ± 2◦C, and a humidity of 40–60%. Mice
had free access to standard rodent diet and tap water. The
NTSR3/sortilin homozygous KO mice were generated by the
Morales’s laboratory by incorporation of a GFP cassette after
exon 1 (Zeng et al., 2009) and the controls were C57Bl/6J
male mice from Janvier Labs (St Berthevin, France). All animal
care and experimental procedures complied with the policies
on the care and use of laboratory animals of European
Community legislation 2010/63/EU and were approved by
the local Ethics Committee (CIEPAL) (protocol number
00893.02).
Pain Behavioral Tests
The writhing test was performed as follows: 20 min prior to acetic
acid injection, mice were injected intraperitoneally with either
100µl of saline or 100µl of a solution containing 1µMof JT212,
a NT analog able to cross the blood-brain-barrier (Hughes et al.,
2010). Writhes were counted over a 15 min period starting from
the fifth min after intraperitoneal injection of a 0.5% acetic acid
solution (10 µl/g).
The Hot plate test was performed with a hot plate apparatus
(Ugo Basile) at 55◦C. We measured the time (in seconds) to paw
licking and jumping latency in response to heat.
Determination of Blood and Central NT
Concentration
Serum samples were collected in the morning by retroorbital
puncture in mice anesthetized by isoflurane 4%. Brain NT
was recovered after acid extraction of brain homogenates as
described (Kokko et al., 2005). The amount of NT was measured
from serum and brain using a method adapted to AlphaScreen
technology (Perkin Elmer, France). The technique necessitated
the preparation of a biotinylated NT on one hand, and of
an antibody against the C-terminus of NT on the other
hand.
Rabbit polyclonal antibodies against the C-terminus of NT
(2-13) were prepared by Agro Bio (La Ferté St Aubin, France).
NT (2-13) (5.4 mg, 3.6 mmol) was solubilized in 1.5 ml of
25 mM phosphate buffer, pH 6.7. N-hydroxysuccinimide biotin
(13.5 mmol) resuspended in 700 µl of 70% acetonitrile, 30%
dimethyl formamide was added to the peptide solution and
incubated overnight at room temperature. Biotin-NT (2-13) was
purified by HPLC using a Waters apparatus equipped with a
semi-preparative RP18 Lichrosorb column. Biotin-NT (2-13)
(eluted at 35min), identified bymass spectrometry, was collected,
quantified by its absorption at 280 nm and lyophylised in
aliquots.
According to the principles of AlphaScreen technology,
streptavidin-donor microbeads were recognized by biotin-NT
(2-13) and the anti-rabbit IgG-acceptor microbeads were bound
by anti-NT (2-13) antibodies. The signal was produced when
the two microbeads (acceptor and donor) were drawn into
proximity by a molecular interaction occurring between the
binding partners captured on the beads. The peptide present in
the sample was able to interfere with this interaction leading to
competition. Standard curves were obtained by incubation in 96-
well plaque of 1 nM biotin-NT (2-13) with the anti-NT (2-13)
antibody (1:5000) in the AlphaLisaTM buffer in the absence or
in the presence of increasing concentrations of NT (2-13) (from
10−11 to 10−6 M) for 1 h at room temperature. After addition of
acceptor and donor beads and further incubation for 2 h at room
temperature, the plaque was read using the Enspire apparatus
(Perkin). Note that non-apparented peptides like somatostatin or
spadin were unable to interfere with the dosing method. For sera
measurements, the same volume of serum was added instead of
unlabeled NT (2-13). The amount of NT was determined from
its percent of signal inhibition and calculated using the standard
curve.
Sub-cellular Fractionation
In order to quantify the amount of NTSRs expressed at
the cell surface and intracellularly, we performed sub-cellular
fractionation from brain homogenates. Plasma membranes were
prepared from brain homogenates of WT or KO-NTSR3/Sortilin
mice according to the protocol previously described (Clancy
and Czech, 1990). 30 µg of crude homogenates, purified plasma
membranes and high and low density vesicles (H/LDM) were
submitted to Western blot analysis using the rabbit polyclonal
antibodies against NTSR1 or NTSR2 (1:500) (SantaCruz
Technologies (USA)). Proteins detected with these antibodies
were normalized using antibodies specific for each intracellular
compartment (NaKATPase for plasma membranes, TGN38
for H/LDM and tubulin for total extracts) from SantaCruz
technologies (USA).
Statistics
Results are expressed as mean ± standard error mean (SEM).
Statistical analyses were performed using GraphPad (version
6.0). Student t-tests were used when appropriate to evaluate
differences in quantitative variables whereas analysis of variance
(ANOVA) was used to compute possible differences between
groups.
RESULTS
Binding of NT to Brain Homogenates from
Wild Type and NTSR3/Sortilin KO Mice
In order to quantify the amount of NT binding sites
corresponding to NTSR1 and NTSR2 in the brain of wild
type (WT) and NTSR3/sortilin deficient mice (KO-NTSR3),
we first performed saturation binding experiments of iodinated
NT on homogenates prepared from the indicated brains in
the absence or in the presence of the NTSR2 selective blocker
levocabastine (1µM) (Kitabgi et al., 1987). In brain homogenates
from WT mice, in the absence of levocabastine, the saturation
curve obtained from a typical experiment indicated a maximal
binding capacity (Bmax) of about 200 fmol/mg (Figure 1A).
In the presence of levocabastine, the Bmax decreased to 65–70
fmol/mg (Figure 1A), a binding capacity corresponding to the
levocabastine insensitive NT binding sites attributed to NTSR1.
Interestingly, in brain homogenates from KO-NTSR3 mice,
saturation experiments performed in the absence or in the
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FIGURE 1 | Binding of 125I-NT to brain homogenates from WT and NTSR3/sortilin KO mice. (A,B) Brain homogenates from WT (A) or from NTSR3/sortilin
KO mice (B) (60 µg of proteins) were incubated with increasing concentrations of 125 I-NT alone or isotopically diluted with unlabeled NT in the absence (closed
symbols) or in the presence (open symbols) of 1 µM levocabastine. Saturation curves were made from specific binding using GraphPad analysis. (C) Representation
of the mean ± SEM of total binding and levocabastine-sensitive and -insensitive binding sites calculated from 5 independent experiments performed in triplicate.
*p < 0.05 using Student t-Test.
presence of levocabastine revealed the same Bmax (Figure 1B),
demonstrating that in KO-NTSR3 mice, the binding of NT
is insensitive to the drug. Figure 1C which summarized the
Bmax mean values obtained from 5 independent experiments,
clearly indicated that the amount of levocabastine-insensitive
NT binding sites increased in KO mice (from 63 ± 12
fmol/mg in WT mice to 124 ± 30 fmol/mg in KO mice, p
= 0.029). As expected, the amount of levocabastine-sensitive
NT binding sites was decreased in brain from KO mice
from 88 ± 19 fmol/mg in WT to 14 ± 9 fmol/mg in KO
(p= 0.028).
Measurement of the Expression of NTSR1,
NTSR2 in Brain Homogenates from Wild
Type and NTSR3/Sortilin KO Mice
Binding experiments performed above suggested a loss of
levocabastine-sensitive NT binding sites (i.e., NTSR2) and an
increase of levocabastine-insensitive NT binding sites (i.e.,
NTSR1) in the brain of KO-NTSR3 mice. For this reason, we
further analyzed the expression of both receptors at the mRNA
and protein levels.
Intriguingly, quantitative PCR (qPCR) determination
indicated that the mRNA of NTSR1 remained unchanged
whereas the amount of NTSR2 mRNA was significantly
increased in the brain of KO mice (p < 0.001) (Figure 2A).
This increase of NTSR2 mRNA was in contradiction with
the loss levocabastine-sensitive NT binding sites. The similar
mRNA level of NTSR1 between WT and KO mice did not
correspond to the increase of levocabastine-sensitive NT binding
sites observed in the brain of KO mice. Therefore, we verified
the protein expression of both receptors after subcellular
fractionation and Western blot analysis. The quantification
determined from 5 independent experiments indicated that
the protein level of NTSR1-like remained similar at the plasma
membranes (PM), in the high and low density vesicles (H/LDM)
and in the total extracts from brain from WT and KO mice
(Figure 2B). However, the amount of NTSR2-like protein
was significantly increased by a factor 2 (p < 0.05) at the
plasma membranes prepared from KO mouse brain but was
similar between WT and KO mice in H/LDM and total extracts
(Figures 2C,D).
Increased Expression of NT in Brain and
Serum from NTSR3/Sortilin KO Mice
As we observed an important increase of NTSR2 expression at
the plasma membrane, we wondered whether the expression of
its ligand may also be modified in NTSR3/sortilin KO mice by
using the dosing method developed for NT. We first observed
that the amount of NT mRNA was also significantly enhanced in
the brain of KO mice (p < 0.05) (Figure 3A). The higher level of
NT mRNA measured in the brain from NTSR3/sortilin KO mice
prompted us to quantify the peptide content in brain extracts
and serum from both mice. To perform these experiments, we
developed tools (specific antibodies and biotinylated NT) to
be used according to the AlphaLisaTM method (Perkin). The
Figure 3B illustrated the competition curve between biotinylated
NT and unlabeled NT. The amount of NT present in the
serum or in the brain extracts was determined from this
curve (Figure 3C). We observed a significant increase of the
peptide in serum (from 12 nM in WT to 18 nM in KO mice)
and brain extracts (from 21 nM in WT to 45 nM in KO)
(Figure 3C).
NTSR3/Sortilin KO Mice Are Resistant to
Pain
Since we observed an increase of both NT and NTSR2 in
NTSR3/sortilin KO mice and that NTSR2 is mainly involved
in NT-induced analgesia (Dubuc et al., 1999), we wondered
whether NTSR2 is still functional using acute pain tests including
chemical (writhing test) and thermal (paw licking) nociceptive
tests. When mice were placed on the hot plate, the latency for
paw licking increased from 8.9 ± 0.85 s for WT mice to 17.3
± 0.95 s for KO mice (p < 0.001) (Figure 4A). Similarly, the
latency to jump was 30.9 ± 1.5 s for WT mice and increased to
39.4 ± 3.7 s for KO mice (p = 0.038) (Figure 4A), suggesting a
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FIGURE 2 | Quantification of NT receptors from WT and NTSR3/sortilin KO mice (A) Quantitative PCR of NTSR1 and NTSR2 from WT and NTSR3/sortilin KO
mouse brains, ***p < 0.001. (B,C) Protein expression of NTSR1-like and NTSR2-like in plasma membranes (PM), high and low density vesicles (HLDM) and total
homogenates prepared from brains from WT and NTSR3/sortilin KO mice. Each bar in the graphs represents the mean ± SEM of bands intensitiy quantified using the
corresponding compartment markers from 5 independent experiments. *p < 0.05 using Mann and Whitney Student t-test. (D) Representative Western blot analysis of
NTSR1-like and NTSR2-like proteins expressed in plasma membranes (PM), high and low density vesicles (HLDM) and total homogenates prepared from brains from
WT and NTSR3/sortilin KO mice. NaK-ATPase; Sodium Potassium-ATPase, TGN38; Trans-Golgi Network protein of 38 kDa.
FIGURE 3 | Measurement of brain and blood NT content in WT and NTSR3/sortilin KO mice (A) Quantitative PCR of NT from WT and NTSR3/sortilin KO
mouse brains. (B) Competitive inhibition of biotinylated NT by unlabeled NT, the standard curve was the mean ± SEM from 3 independent experiments performed in
triplicate, the corresponding IC50 was 0.48 nM. (C) NT concentrations in sera and in brain from WT and NTSR3/sortilin KO mice measured using AlphaLisaTM
technique. Each bar in the graphs represents the mean value ± SEM of NT concentrations determination in serum (n = 19) and in brain extracts (n = 3). *p < 0.05.
resistance to pain for KO-NTSR3 mice. When WT mice were
subjected to the writhing test, the number of writhes/15 min
was 38.5 ± 5.2 (Figure 4B). In KO-NTSR3 mice, the number
of writhes was 13.8 ± 3.6, a value significantly different to that
obtained in WT mice (p < 0.001). Therefore, we tested the effect
of IP injection of JT212 (100 µl of a 1 µM solution) on the pain
writhing test and as expected, JT212 significantly decreased the
number of writhes to 22.6 ± 3.7 in WT mice (One way ANOVA,
p = 0.028) (Figure 4B). In KO mice, the injection of the peptide
was without significant effect on the number of writhes (12.5 ±
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FIGURE 4 | Analgesic responses of WT and NTSR3/sortilin KO mice (A) Hot plate test, mice were placed on a plate at a temperature of 55◦C. Bars represent
mean ± SEM of paw licking and jumping latencies. Paw licking latency, ***p < 0.001, n = 20; jumping latency, *p < 0.05, n = 20. (B) Writhes were counted over a 15
min period after intraperitoneal injection of 0.5% acetic acid after intraperitoneal injection of either vehicle (NaCl) or 100 µl of 1 µM JT212. The number of indicated
writhes is the mean ± SEM from groups of 10–12 mice. ***p < 0.001, *p < 0.05, n.s: non-significant.
2.4 (p = 0.99) (Figure 4B) indicating that no further analgesic
action of JT212 was measurable when animals were already
desensitized.
DISCUSSION
In the present work, we provide evidence that the absence of
NTSR3/sortilin leads to modificiation of the neurotensinergic
system with the consequence that these mice are less sensitive to
pain as clearly shown by the two different tests (Figure 4). This
particular behavior is likely due to the increase of both NTSR2,
the NT receptor mainly involved in the analgesic effect of NT
(Dubuc et al., 1999), and NT itself.
However, in the first series of experiments we performed to
analyze the amount of levocabastine-sensitive and -insensitive
NT binding sites from WT and KO mice brains, we obtained
contradictory results. Binding experiments revealed that in the
brain from KO mice, the amount of levocabastine-sensitive
binding sites, predicted to be NTSR2 (Kitabgi et al., 1987; Mazella
et al., 1996), was dramatically decreased whereas levocabastine-
insensitive binding sites appeared to be enhanced (Figure 1). By
constrast, qPCR and Western blot analyses indicated no change
in the NTSR1 content and a significant increase of NTSR2 at
the plasmamembranes prepared fromNTSR3/sortilin KOmouse
brain (Figure 2). A possible explanation is that the sensitivity
of NTSR2 to levocabastine as well as its relatively low affinity
to NT are likely due to its interaction with NTSR3/sortilin as
already observed in beta cells (Beraud-Dufour et al., 2009). In
the absence of NTSR3/sortilin, NTSR2 could be less retained
intracellularly and the conformation of NTSR2 protein could
prevent the binding of levocabastine and could increase its
affinity for NT. Growing evidences have demonstrated that homo
and heterodimerizations of GPCRs are involved in receptor
recognition, cellular trafficking and signaling (for review see
Fuxe et al., 2014). Concerning the neurotensinergic system,
NTSR1 has been shown to be functionally associated with
dopamine D2 receptor to modulate its activity (Borroto-Escuela
et al., 2013). Heterodimerization between NTSR1 and NTSR2
was also observed leading to modifications of intracellular
NTSR1 distribution, trafficking and functionality (Perron et al.,
2007; Hwang et al., 2010). In the present case, the increase
of NTSR2 expression could lead to a general dysfunction of
the neurotensinergic system by decreasing also the activity of
NTSR1. A similar interaction between NTSR3/sortilin and NT
receptors has been already demonstrated for NTSR1 expressed
in the colonic adenocarcinoma cell line HT29 in which its
physical association with NTSR3/sortilin led to a decrease
of both the affinity of NT for NTSR1 and the NTSR1-
mediated biological response (i.e., IPs turnover) (Martin et al.,
2002).
Another interesting finding was the increase in the expression
of NTSR2 concomittant to an increase of NT content both in the
brain and in the blood from NTSR3/sortilin KO mice (Figure 3).
The higher level of NT in the brain was correlated with the higher
mRNA content for the peptide whereas the origin of the higher
amount of NT measured in the serum from NTSR3/sortilin KO
mice remains to be elucidated.
From the latter observations, we hypothesized that
NTSR3/sortilin KO mice would likely behave differently
than WT mice when subjected to pain, with modified sensitivity
to thermal and chemical stimuli. As expected, there is a lower
sensitivity of KO mice vs. WT mice to high temperatures as
measured by paw licking and jump latency, and to intraperitoneal
injection of acetic acid as measured by the number of writhes,
corresponding to expected results from mice with a high content
of NT (Kleczkowska and Lipkowski, 2013). These results confirm
the importance of the neurotensinergic system in the control of
pain modulation. The involvement of both NTSR1 and NTSR2
in the effect of NT on analgesia has been largely demonstrated in
the literature either by using ligands selective for each receptor
(Sarret et al., 2005; Smith et al., 2012) or by using mice in which
NTSR1 or NTSR2 genes have been deleted (Maeno et al., 2004;
Roussy et al., 2010).
In conclusion, the work presented here incorporated
a new physiological concept that should be taken into
account for further investigations for the development of
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NT analogs to be used in pain treatment. This concept
is that a small increase of NT production in the brain,
associated with an increase of NTSR2 expression, appears
to be sufficient to reduce the sensitivity of animals to
pain.
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